| Identification | More | [Name]
Alagebrium chloride | [CAS]
341028-37-3 | [Synonyms]
2-(4,5-dimethyl-1,3-thiazol-3-yl)-1-phenyl-ethanone chloride
4,5-dimethyl-3-(2-oxo-2-phenylethyl)thiazolium chloride
alagebrium chloride
ALT-711
Dimethyl-3-(2-oxo-2-phenyl)-chloride
(Alagebrium) (thiazolium salt) | [EINECS(EC#)]
636-473-0 | [Molecular Formula]
C13H14ClNOS | [MDL Number]
MFCD09027398 | [Molecular Weight]
267.77 | [MOL File]
341028-37-3.mol |
| Hazard Information | Back Directory | [Uses]
Prevention and treatment of cardiovascular complications
of aging, diabetes, and end stage renal disease;
diabetic multisymptom pathology (other than cardiovascular)
including retinopathy, neuphropathy, neuropathy, and
ulcers (advanced glycosylation endpr. | [in vivo]
Blood pressure is not affected by treatment with Alagebrium.? In diabetic RAGE apoE double-KO mice, treatment with Alagebrium is associated with a modest reduction in renal mass and reduces hyperfiltration compare with nontreated mice. Treatment with Alagebrium in diabetic RAGE apoE double-KO mice is associated with a further reduction in glomerular collagen IV levels, approaching levels observed in control mice[1]. Body weight, heart rate (HR), and mean blood pressure (BP) are similar in Zucker lean (ZL), obese (ZO), and diabetic (ZD) groups in the absence or presence of Alagebrium (ALT-711). Alagebrium increases blood flow (BF) in ZO rats but reduces distal vascular resistance in ZD rats. A decrease in neointimal hyperplasia (NH) intrastrut thickness as a function of local radius is found in all groups with Alagebrium treatment.? A significant increase in TGF-β expression is also found in the AAo of ZL rats treated with Alagebrium[2]. | [storage]
Store at -20°C |
|
|